Drug Profile
BXCL 702
Alternative Names: BXCL-702Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator Inveni
- Developer BioXcel Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Enzyme inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
- No development reported Acute myeloid leukaemia; Diffuse large B cell lymphoma
Most Recent Events
- 28 Mar 2024 Preclinical trials in Solid tumours in USA (IV)
- 16 Mar 2021 No development reported - Phase-I/II for Acute myeloid leukaemia (IV)
- 16 Mar 2021 No development reported - Phase-I/II for Diffuse large B cell lymphoma (IV)